Clinical trials
Locally Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting locally advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 4,342 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT07743944Recruiting
Breast cancer second-line treatment patterns in China
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
Nanjing, JiangsuAges 18 years+ - NCT06121453Recruiting
Adherence support for metastatic breast cancer patients
This study tests a program to help people with metastatic breast cancer take their endocrine therapy, CDK4/6 inhibitors, and heart-related medications as prescribed. If you sometimes miss doses of these medicines, you may be able to join.
New York, New YorkAges 18–99 - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-negative breast cancer
This trial tests a new drug called Dato-DXd for people with a specific type of breast cancer that is hormone receptor-positive and HER2-negative (IHC 0). It's for those whose cancer has stopped responding to hormone therapy and who haven't had chemotherapy for cancer that has spread.
Largo, FloridaAges 18 years+ - NCT07258563Recruiting
Can a special diet prevent taste changes from chemo?
This study looks at whether a special diet can help prevent taste changes during chemotherapy. It is for people with certain cancers who are about to start treatment.
AmsterdamAges 18–70 - NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT04019678Recruiting
Breast cancer study after chemotherapy with small underarm node spread
This study looks at whether it’s safe and effective to avoid removing many underarm lymph nodes in some people who, after chemotherapy, still seem to have only tiny (“micro”) cancer deposits in the sentinel lymph node. It may help reduce treatment side effects while keeping cancer control.
Rozzano, MIAges 18–75 - NCT04020575RecruitingPhase 1
CAR T cells made from your blood for advanced breast cancer
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
Duarte, CaliforniaAges 18 years+ - NCT04158843Recruiting
Local surgery vs comfort treatment for limited breast cancer spread
This trial compares a more direct local treatment (targeting a small, limited spot) versus a comfort-focused palliative approach for breast cancer that has spread only to one side of the upper arm bone or breastbone area. It aims to see which approach works better while keeping side effects manageable.
Hangzhou, ZhejiangAges 18–75 - NCT04159142RecruitingPhase 2
Testing two chemo combos for advanced triple-negative breast cancer
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
Shijiazhuang, HebeiAges 18–70 - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT04646759RecruitingPhase 3
Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Guangzhou, GuangdongAges 18–80 - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT04740424RecruitingPhase 1
First study of a new drug for advanced solid cancers
This Phase 1 trial tests a brand-new treatment (given at increasing doses) for people with advanced, unresectable, or metastatic solid tumors. It mainly looks at safety and how the drug behaves in the body, and it may help if standard treatments didn’t work or aren’t suitable.
Waratah, New South WalesAges 18 years+ - NCT04744506Recruiting
Targeted removal of armpit nodes after chemotherapy for breast cancer
This trial studies a more targeted surgery to remove cancer-involved lymph nodes in the armpit after you finish chemotherapy before surgery. It may help doctors better remove affected nodes while avoiding unnecessary tissue removal.
Hangzhou, ZhejiangAges 18–85 - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT07624617Recruiting
Fasting and Breast Cancer Treatment Study
This study looks at whether periods of fasting (eating for shorter time windows) might help improve how well a breast cancer medication called capivasertib works. You'll wear a glucose monitor, track your food, and follow fasting schedules while continuing your regular cancer treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT04947189RecruitingPhase 1/Phase 2
Seviteronel plus chemo for advanced triple-negative breast cancer
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
Darlinghurst, New South WalesAges 18 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05099809Recruiting
Hyperthermia plus treatment for locally advanced cancers
This registry study looks at whether adding hyperthermia (raising body temperature) is safe and effective for people with certain locally advanced, non-spread cancers. It will follow outcomes to help doctors understand who may benefit and what side effects to expect.
Sevāgrām, MaharashtraAges 18 years+ - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 4,342 recruiting locally advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced/Metastatic Breast Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.